BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li JA, Xu XF, Han X, Fang Y, Shi CY, Jin DY, Lou WH. Nab-Paclitaxel Plus S-1 Shows Increased Antitumor Activity in Patient-Derived Pancreatic Cancer Xenograft Mouse Models. Pancreas 2016;45:425-33. [PMID: 26495780 DOI: 10.1097/MPA.0000000000000501] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Dai YH, Yu XJ, Xu HT, Zhuang L, Zhang MS, Zou YM, Fu Q, Qiu H, Yuan XL. Nab-paclitaxel plus S-1 versus oxaliplatin plus S-1 as first-line treatment in advanced gastric cancer: results of a multicenter, randomized, phase III trial (GAPSO study). Ther Adv Med Oncol 2022;14:17588359221118020. [PMID: 35983025 DOI: 10.1177/17588359221118020] [Reference Citation Analysis]
2 Cui Y, Yu Y, Yu S, Li W, Wang Y, Li Q, Liu T. Phase I study of adjuvant chemotherapy with nab-paclitaxel and S-1 for stage III Lauren's diffuse-type gastric cancer after D2 resection (NORDICA study). Cancer Med 2023;12:1114-21. [PMID: 35751496 DOI: 10.1002/cam4.4966] [Reference Citation Analysis]
3 Zong Y, Peng Z, Wang X, Lu M, Shen L, Zhou J. Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma. Cancer Manag Res 2020;12:12657-66. [PMID: 33328763 DOI: 10.2147/CMAR.S263773] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
4 Guo X, Xu Y, Ji Y, Fan Y, Wang D, Jin D, Zhuang R, Wu L, Lou W, Zhou Y. Efficacy and toxicity comparison of nab-paclitaxel plus S-1 and nab-paclitaxel plus gemcitabine as first-line chemotherapy for metastatic pancreatic cancer. Journal of Pancreatology 2020;3:35-41. [DOI: 10.1097/jp9.0000000000000038] [Reference Citation Analysis]
5 Feng R, Morine Y, Ikemoto T, Imura S, Iwahashi S, Saito Y, Shimada M. Nab-paclitaxel interrupts cancer-stromal interaction through C-X-C motif chemokine 10-mediated interleukin-6 downregulation in vitro. Cancer Sci. 2018;109:2509-2519. [PMID: 29902349 DOI: 10.1111/cas.13694] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 4.4] [Reference Citation Analysis]
6 Rubio-Manzanares Dorado M, Marín Gómez LM, Aparicio Sánchez D, Pereira Arenas S, Praena-Fernández JM, Borrero Martín JJ, Farfán López F, Gómez Bravo MÁ, Muntané Relat J, Padillo Ruiz J. Translational pancreatic cancer research: A comparative study on patient-derived xenograft models. World J Gastroenterol 2018; 24(7): 794-809 [PMID: 29467550 DOI: 10.3748/wjg.v24.i7.794] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
7 Shi Y, Zhang S, Han Q, Li J, Yan H, Lv Y, Shi H, Liu R, Dai G. Nab-paclitaxel plus S-1 in advanced pancreatic adenocarcinoma (NPSPAC): a single arm, single center, phase II trial. Oncotarget 2017;8:92401-10. [PMID: 29190925 DOI: 10.18632/oncotarget.21359] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
8 Giordano G, Pancione M, Olivieri N, Parcesepe P, Velocci M, Di Raimo T, Coppola L, Toffoli G, D’Andrea MR. Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions. World J Gastroenterol 2017; 23(32): 5875-5886 [PMID: 28932079 DOI: 10.3748/wjg.v23.i32.5875] [Cited by in CrossRef: 62] [Cited by in F6Publishing: 62] [Article Influence: 10.3] [Reference Citation Analysis]